SRY, SOX9, and DAX1 are key genes in human sex determination, by virtue of their associated male-to-female sex reversal phenotypes when mutated (SRY, SOX9) or over-expressed (DAX1). During human sex determination, SRY is expressed in 46,XY gonads coincident with sex cord formation, but also persists as nuclear protein within Sertoli cells at 18 weeks gestation. High-level SOX9 expression in the sex cords of the testis parallels that seen during mouse development, however in humans, SOX9 transcripts also are detected in the developing ovary. Low-level DAX1 expression predates peak SRY expression by at least 10 days, and persists in Sertoli cells throughout the entire sex determination period. In Dosage Sensitive Sex reversal, the anti-testis properties of DAX1 over-expression could act prior to the peak effects of SRY and continue during the period of SOX9 expression. These ®ndings highlight expression differences for the SRY, SOX9, and DAX1 genes during sex determination in humans and mice. These results provide a direct framework for future investigation into the mechanisms underlying normal and abnormal human sex determination. q
Results and discussion
Mutation of the human genes which encode SRY (Sexdetermining Region of the Y chromosome) and SOX9 (SRYrelated HMG BOX gene 9) results in 46,XY pure gonadal dysgenesis (Berta et al., 1990) and Campomelic Dysplasia, respectively (Wagner et al., 1994; Foster et al., 1994) . Duplication of the Xp21 region is associated with Dosage Sensitive Sex reversal (DSS; Bardoni et al., 1994) , and includes the DAX1 gene [DSS-Adrenal Hypoplasia Congenita (AHC) critical region on the X chromosome gene 1, of®cially designated AHC in humans and Ahch in mice].
Insight into the mechanisms, which underlie all three of these male-to-female sex reversal disorders, has relied heavily upon rodent models. However, there is increasing evidence of inter-species differences in the sex-determining mechanisms. Testicular determination by Sry in Mus musculus requires a C terminus region, which includes a transactivation domain not encoded by the human SRY gene (Dubin and Ostrer, 1994; Bowles et al., 1999) . Neither human SRY nor SOX9 transgenes are able to substitute for their mouse paralogs in transgenic experiments (Wunderle et al., 1998) . Furthermore, sex reversal in a mouse model of DSS required the weak Sry allele of M. domesticus poschiavinus and Dax1 over-expression in excess of that anticipated from simple duplication of Xp21 (Swain et al., 1998) . To provide a direct framework for understanding the roles of SRY, DAX1, and SOX9 in human sex determination, we performed in situ hybridization on sections from precisely staged human embryos (O'Rahilly and Muller, 1987; Bullen and Wilson, 1997) .
Formation of the indifferent gonadal ridge has commenced by 33 days post-ovulation (d.p.o.), which is Carnegie stage 15 (CS15), at which time the gonad contains both somatic and primordial germ cells (Fig. 1A) . During the indifferent gonadal stages, the histology of the urogenital ridge is indistinguishable between males and females. SRY expression commences in the gonadal ridge of 46,XY embryos between 41 and 44 d.p.o./CS17-18 (Fig. 1B,C) . Peak SRY expression is detected at 44 d.p.o./CS18, when sex cords are ®rst visible, thereby de®ning testicular determination (Fig. 1C) . By 52 d.p.o./CS21, primordial germ cells are surrounded by differentiating Sertoli cells within the developing sex cords (arrow, Fig. 1D ). SRY transcripts persist at low levels within these sex cords throughout the embryonic period and beyond, a ®nding which differs from the expression observed in mouse (Jeske et al., 1995) . To further investigate this ongoing low-level expression, immunocytochemistry was performed. Accordingly, SRY protein was detected within the nuclei of fetal Sertoli cells at 18 weeks gestation ( CS18 and 21 in presumptive testes (Fig. 3B,C) . This expression is maintained in the sex cords up to 18 weeks gestation, in keeping with the presence of SOX9 in Sertoli cells (Fig.  3D ). In 46,XX female embryos, no SOX9 expression is apparent in the gonads prior to 48 d.p.o./CS19, consistent with a primary role for SOX9 in testicular determination. Later, low level ovarian SOX9 transcripts are detected in the region of the embryonic rete ovarii (Fig. 4, 52 d.p.o./CS21). Similar expression is still apparent within the fetal ovary at 14 weeks gestation (data not shown). In female mice, Sox9 expression is completely extinguished in the gonad coincident with sexual differentiation, and remains undetectable within the developing ovary (Morais da Silva et al., 1996; Kent et al., 1996) . This ovarian expression in human embryos lies anterior to similar levels of detection within the tubules of the de®nitive kidney. Developmental renal abnormalities have been described in Campomelic dysplasia (Houston et al., 1983) , therefore a low level of renal expression may carry functional signi®cance.
DAX1 expression is apparent within the indifferent 46,XY gonadal ridge at 33 d.p.o./CS15 (Fig. 5A ). This subtle detection of transcripts overlies higher expression within the developing adrenal cortex, and parallels the early expression pro®le of steroidogenic factor 1 (Hanley et al., 1999) . This low-level expression of DAX1 continues unchanged throughout the period of the indifferent gonad, and persists following testicular determination, where transcripts are mainly detected over the developing sex cords at 52 d.p.o./CS21, a pattern that is consistent with Sertoli cell expression (Fig. 5A) . Identical low-level expression occurs within the female gonadal ridge at 33 d.p.o./CS15, and continues unchanged pre-and post-sex determination (Fig.  5B and data not shown) . The gonadal expression in both sexes is consistently lower than in the neighboring adrenal cortex, an internal positive control for these experiments (Fig. 5A,B) . The same low level distribution of transcripts continues within the fetal testis and ovary at 18 and 15 weeks respectively (data not shown). Although inconsistent results have been reported between mice and rats Nachtigal et al., 1998) , these human ®ndings differ from the transgenic model of DSS. The later onset of mouse Dax1 expression occurs coincident with the upregulation of Sry and sexual dimorphism is observed post-sex determination with increased ovarian Dax1 expression (Swain et al., , 1998 .
In summary, these studies describe the sequential expression pro®les of the genes, SRY, SOX9, and DAX1 during human sex determination. Knowledge of these expression patterns during normal human development provides a direct framework for the investigation of the male-to-female (A,B) . g, gonad; c, sex cords; t, testis; i, interstitium; gm, gut mesentery; m, mesonephric tubules. Scale bar represents 80 mm. sex reversal associated with their mutation or over-expression.
Experimental procedures

Carnegie staging of human embryo sections
Collection and use of human embryonic and fetal material was carried out following ethical approval from the Newcastle Health Authority and with the appropriately signed consents (O'Rahilly and Muller, 1987; Bullen and Wilson, 1997) . Fetal material was obtained following second trimester termination, immediately dissected, ®xed and embedded as above. Both embryonic and fetal material was sexed by karyotype analysis.
In situ hybridization
Riboprobe templates were as follows: SRY, nucleotides 3411-3696 of GenBank Accession No. L08063; SOX9, nucleotides 2488-3125 of GenBank Accession No. Z46629; DAX1, nucleotides 1041±1719 of GenBank Accession No. S74720. All cDNA templates were sequenced prior to use. Results were duplicated with riboprobes generated from at least one other speci®c cDNA template for each gene. Expression for all genes under study was analyzed on sections within 20 mm for all Carnegie stages in both sexes. In situ hybridization was performed as described previously (Hanley et al., 1999) .
Alkaline phosphatase staining
De-waxed slides were treated for 20 min in Triton X-100 and subjected to the color substrates NBT/BCIP, prior to washing in distilled water and mounting. Sections are within 10 mm of the corresponding in situ hybridization section.
SRY immunocytochemistry
Mouse monoclonal SRY antibody was prepared, characterized, and used as described previously (Salas-Corte Âs et al., 1999) . Negative controls in this study included omission of primary and secondary antibodies.
